REG - Primary Health Props - Scrip dividend reference price

Primary Health PropertiesAnnouncement

07/04/2022 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220407:nRSG6645Ha&default-theme=true

RNS Number : 6645H  Primary Health Properties PLC  07 April 2022

 

Primary Health Properties PLC

(the "Company")

 

Scrip Dividend Scheme

 

The Company announces that the scrip dividend reference price for the Second
Quarterly Interim Dividend in 2022 (the "Interim Dividend"), payable on 20 May
2022, is 149.58 pence.

 

The reference price is the price at which Primary Health Properties PLC
ordinary shares of 12.5p each ("Ordinary shares") will be issued to
shareholders who have elected to receive shares in lieu of cash dividends
through participation in the Scrip Dividend Scheme and is the average of the
closing middle market quotations of the Ordinary shares derived from the
London Stock Exchange Daily Official List for the day on which the Ordinary
shares were first quoted as ex-dividend (31 March 2022) and the four
subsequent dealing days (being 1,4,5 and 6 April 2022).

 

Any shareholders entitled to the Interim Dividend who do not already
participate in the Scrip Dividend Scheme (or whose mandates are not deemed
valid and effective, as explained above) and wish to do so, may obtain a
mandate form either by contacting the Company's Registrar, Equiniti, on 0871
384 2268, or by downloading from the Company's website
www.phpgroup.co.uk/Investors, or from the National Storage Mechanism. This
form must be completed and returned to Equiniti to arrive no later than the
close of business on 6 May 2022 in order for it to be effective for the
Interim Dividend.

 

 

Contacts:

 

Paul Wright, Company Secretary

Telephone: 0203 833 3344

 

Legal Entity Identifier: 213800Y5CJHXOATK7X11

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DIVIRMMTMTBMBPT